Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy - Scorecard - MDSpire

Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy

  • By

  • Javier Cifuentes-Quin

  • Yiselle T. Garcia-Montañez

  • Alexandra Hurtado-Ortiz

  • Jhonatan Cruz

  • Luis Carlos Lagares

  • Luis A. Olarte-Licht

  • Maricel Licht-Ardila

  • Edgar Fabián Manrique-Hernández

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Comparison of Acute and Late Toxicity in Prostate Cancer Patients Undergoing Moderately Hypofractionated versus Ultra-Hypofractionated Radiotherapy

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationMale patients aged ≥18 years with histopathologically confirmed non-metastatic prostate adenocarcinoma (T1–T4)
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

    • Definitive external beam radiotherapy using IMRT/VMAT with daily IGRT (refer to [specific guidelines])

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        229 patients with non-metastatic prostate cancer

        Comparison of MHRT and UHRT toxicity outcomes

        Clinical Best Practices

        • evidence

        Related Resources & Content

        Original Source(s)

        Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy

        • by Javier Cifuentes-Quin, Yiselle T. Garcia-Montañez, Alexandra Hurtado-Ortiz, Jhonatan Cruz, Luis Carlos Lagares, Luis A. Olarte-Licht, Maricel Licht-Ardila, Edgar Fabián Manrique-Hernández

        • May 22, 2026

        Related Content

        Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

        CD38+ NK cells: novel players in immunoregulation

        Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications